CTOs on the Move

Tobii Dynavox

www.tobiidynavox.com

 
Tobii Dynavox, a wholly owned subsidiary of Tobii AB (publ), is the leading global provider of eye tracking enabled and touch-based augmented and alternative communication (AAC) devices as well as symbol-based products for individuals with special needs.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

CHF Solutions

CHF Solutions is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Penumbra

Penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. We design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. Today we have over 1,300 employees with sales operations in North America, Europe, Latin America, Australia and Asia. Members of the Penumbra team agree that this is where their work has meaning -- we are transforming the treatment of some of the world`s most devastating conditions. Penumbra is where everyone`s ideas matter, and where learning and growth are constant.

XinVivo

XinVivo – a UNC spin-out founded in 2015 and based off Airport Boulevard in Morrisville. The company specializes in developing and manufacturing 3D imaging systems. Specifically, the company is developing carbine nanotube X-ray source array technology, which it claims increases speed while reducing radiation and costs.

Bronzini Dental Group

Bronzini Dental Group is a Millbrae, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Cardiac Therapeutics Inc

Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.